对与不同SERPINA1基因型相关的循环α-1-抗素聚合物的量化
Alice M Balderacchi1, Mattia Bignotti2, Stefania Ottaviani1
1Centre for Diagnosis of Inherited Alpha-1 Antitrypsin Deficiency, UOC Pulmonology, 18631Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Clinical chemistry and laboratory medicine
|February 26, 2024
概括
在α-1-抗素缺乏症 (AATD) 中量化循环聚合物 (CP) 揭示了疾病生物标志物. 患有特定AATD基因型的患者中CP水平升高与疾病严重程度相关,可以识别聚合物形成的AAT变体.
科学领域:
- 遗传学和分子生物学
- 生物化学 生物化学
- 临床诊断 临床诊断 临床诊断
背景情况:
- 阿尔法-1-抗素缺乏症 (AATD) 是由SERPINA1基因突变引起的遗传疾病,导致阿尔法-1-抗素 (AAT) 水平降低.
- 低AAT水平增加了由于中性粒细胞弹性酶活动不受控制的肺气风险.
- AAT变体,特别是Z-AAT突变体,通过细胞内聚合物积累引起肝病;循环聚合物 (CP) 可能表明这一点.
研究的目的:
- 准确量化各种SERPINA1基因型的个体中循环聚合物的百分比 (CP).
- 评估CP作为肝脏内AAT积累和AATD疾病严重程度的生物标志物的潜力.
主要方法:
- 使用敏感的三明治ELISA测量了循环聚合物 (CP) 度.
- 该试验使用聚合物特异的2C1单克隆抗体进行捕获.
- 测量是在血或干血斑 (DBS) 样本上进行的.
主要成果:
- 患有PI*SZ和PI*ZZ基因型的患者的CP水平显著升高,显示出相当大的基因型内变异性.
- 较高的CP百分比与较高的C-反应蛋白水平相关.
- 在携带Mmalton,Mprocida,I,Plowell和Mherleen变种的携带者中也观察到CP的增加,特别是当与Z-AAT.异构体时.
结论:
- 对临床实验室来说,CP量化很有价值,为AATD提供了洞察力.
- 具有相同基因型的患者的可变CP值可能与不同肺部和肝脏疾病的严重程度相关.
- 通过CP测量,可以识别新型,超罕见的AAT变体的聚合性潜力.
相关概念视频
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...